In a report released yesterday, Yigal Nochomovitz from Citi maintained a Buy rating on Alpha Tau Medical Ltd, with a price target of $8.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Yigal Nochomovitz has given his Buy rating due to a combination of factors that highlight the potential growth and strategic advancements of Alpha Tau Medical Ltd. The company is actively progressing with over 15 clinical trials, focusing on innovative treatments for pancreatic cancer, glioblastoma, and squamous cell carcinoma (SCC) using their Alpha DaRT technology. This extensive pipeline suggests a promising future for the company as it aims to enroll the first U.S. patients in pilot studies for pancreatic and glioblastoma cancers, and complete enrollment for the pivotal Phase 3 ReSTART trial for SCC.
Additionally, the anticipated response from the PMDA regarding pre-market approval for treating recurrent head and neck cancer is expected to reduce risks associated with the Alpha DaRT platform. This regulatory milestone, along with planned pivotal readouts and subsequent filings, positions the company for significant advancements. Financially, Alpha Tau Medical Ltd concluded the second quarter of 2025 with a solid cash reserve of $83.3 million, supporting its ongoing and future initiatives. The expected share price return of 127.3% further underscores the positive outlook on the stock.